# Innova Captab (NSE: INNOVACAP) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/INNOVACAP · Pivot · prices to 22 Oct 2026

Innova Captab (NSE: INNOVACAP) closed at ₹983.60 on 22 Oct 2026, up 0.57% on the day. With a market capitalisation of ₹5,629 Cr, it ranks 743rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 40× trailing earnings, against a return on equity of 12.9% in FY26. Over the past year the share price has risen 17.9%. Its 52-week range is ₹622.00 (2 Mar 2026) to ₹1,353.50 (23 Sep 2026); the last close is 27.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹448 Cr (+42.3% year on year) and net profit ₹38 Cr (+28.8%), on a consolidated basis. Promoters held 50.90% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹983.60 |
| Market cap | ₹5,629 Cr |
| P/E (trailing) | 40 |
| ROE | 12.9% (FY26) |
| ROCE | 15.3% (FY26) |
| Debt to equity | 0.31 |
| 52-week high | ₹1,353.50 (23 Sep 2026) |
| 52-week low | ₹622.00 (2 Mar 2026) |
| 1-year return | +17.9% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹448 Cr | +42.3% | ₹38 Cr | +28.8% | ₹6.65 |
| Q3 FY26 | ₹450 Cr | +42.3% | ₹42 Cr | +23.2% | ₹7.37 |
| Q2 FY26 | ₹380 Cr | +19.5% | ₹30 Cr | −15.2% | ₹5.18 |
| Q1 FY26 | ₹352 Cr | +19.5% | ₹31 Cr | +5.2% | ₹5.42 |
| Q4 FY25 | ₹315 Cr | +19.8% | ₹30 Cr | +3.0% | ₹5.17 |
| Q3 FY25 | ₹316 Cr | +4.6% | ₹34 Cr | +36.1% | ₹5.97 |
| Q2 FY25 | ₹318 Cr | +12.5% | ₹35 Cr | +52.8% | ₹6.12 |
| Q1 FY25 | ₹294 Cr | +26.2% | ₹29 Cr | +67.6% | ₹5.15 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,244 Cr | ₹128 Cr |
| FY24 | ₹1,081 Cr | ₹94 Cr |
| FY23 | ₹926 Cr | ₹68 Cr |
| FY22 | ₹801 Cr | ₹64 Cr |
| FY21 | ₹411 Cr | ₹35 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 50.90%
- Foreign institutions: 0.34%
- Domestic institutions: 19.92%
- Non-institutions: 28.84%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |
| [Nephrocare Health Services](https://app.pivotnow.in/stock/NEPHROPLUS) | ₹599.90 | ₹6,019 Cr | 74.1 | — |
| [Sun Pharma Advanced Research Company](https://app.pivotnow.in/stock/SPARC) | ₹176.82 | ₹5,738 Cr | 3.7 | — |
| [Senores Pharmaceuticals](https://app.pivotnow.in/stock/SENORES) | ₹1,233.30 | ₹5,680 Cr | 46.7 | — |
| [FDC](https://app.pivotnow.in/stock/FDC) | ₹339.20 | ₹5,523 Cr | — | — |
| [IOL Chemicals and Pharmaceuticals](https://app.pivotnow.in/stock/IOLCP) | ₹173.27 | ₹5,086 Cr | 36.9 | — |

## Questions and answers

### What is the share price of Innova Captab today?

Innova Captab (NSE: INNOVACAP) last closed at ₹983.60 on 22 Oct 2026. Its 52-week high is ₹1,353.50 and its 52-week low is ₹622.00.

### What is the market cap of Innova Captab?

Innova Captab's market capitalisation is ₹5,629 Cr (₹5,629 Cr) at the 22 Oct 2026 close, ranking 743rd among the NSE companies Pivot tracks.

### What is the P/E ratio of Innova Captab?

Innova Captab trades at a trailing P/E of 40. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 36.9.

### What is the ROE and ROCE of Innova Captab?

Return on equity was 12.9% in FY26 and return on capital employed was 15.3% in FY26 (consolidated figures).

### Is Innova Captab a debt-free company?

No. Innova Captab's debt-to-equity ratio was 0.31 in FY26, with total debt of ₹215 Cr.

### What were Innova Captab's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Innova Captab reported revenue of ₹448 Cr, +42.3% year on year, and net profit of ₹38 Cr, +28.8% year on year.

### How has Innova Captab stock performed over the last year?

Innova Captab's share price has risen 17.9% over the past year, +1.0% over three months and −17.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Innova Captab?

As of 30 Jun 2026: promoters 50.90%, foreign institutions 0.34%, domestic institutions 19.92%, non-institutions 28.84%.

### Who are Innova Captab's competitors?

The listed Pharma & Healthcare companies closest to Innova Captab by market cap are Kovai Medical Center & Hospital, Nephrocare Health Services, Sun Pharma Advanced Research Company, Senores Pharmaceuticals, FDC and IOL Chemicals and Pharmaceuticals.

### Is Innova Captab a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Innova Captab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INNOVACAP against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.